Alembic Share Price Target 2025, 2026, 2030, 2040, 2050
Alembic is an Indian company. It develops and sells pharmaceutical products, such as medicines and the active ingredients used in those medicines. The company works in one main area, which is Pharmaceuticals. In this area, it focuses on producing and selling active pharmaceutical ingredients (APIs) that are made through fermentation and chemical processes. It also carries out research and development activities in the city of Vadodara. The company mainly produces three important products: Azithromycin, Venlafaxine, and Telmisartan.
What is Alembic Ltd NSE: ALEMBICLTD?
Contents
- 1 What is Alembic Ltd NSE: ALEMBICLTD?
- 2 Share price Target Tomorrow
- 3 Alembic share price Target 2025
- 4 Alembic share price Target 2026
- 5 Share price Target 2027
- 6 Share price Target 2028
- 7 Share price Target 2029
- 8 Alembic Share Price Target 2030
- 9 Share price Target 2040
- 10 Share price Target 2050
- 11 Should I buy Alembic stock?
- 12 Alembic Earning Results
- 13 Is Alembic stock good to buy? (Bull case & bear case)
- 14 Conclusion
- 15 FAQs
Alembic was established in 1907 in Vadodara, Gujarat, India. It was started by Mr Vikram Singh and is one of the oldest and most well-known pharmaceutical companies in India. It makes and sells medicines, including active pharmaceutical ingredients (APIs), formulations, and related products.
They are also known for making generic medicines and over-the-counter (OTC) products. The company works in areas like cancer treatment, heart health, and skincare. It sells its products in India and many other countries. It follows strict quality standards and meets international guidelines like those of the U.S. FDA and EU GMP. Alembic also works in biotechnology and research to develop new medicines.
The all-time high price was recorded in the last year and after reaching that point the share price is falling continuously. For 2-3 months, the price has followed a bearish trendline in the daily time frame. The price took little retracement of upside and ultimately can’t sustain. For buying this stock just wait for a breakout of this trendline and trade at your own risk.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -3.7 | +8.0 |
Its main businesses are making Active Pharmaceutical Ingredients (APIs) and developing real estate. The company has certifications (ISO-14001 and ISO-9002), which show it follows good quality and safety standards, and its factories meet the World Health Organization’s guidelines for manufacturing medicines. It also does business in real Estate, Its third real estate project, called VEDA II, is still in the beginning stages of building. Besides its work in medicine and real estate, It also generates power. It has a power plant that produces 11 MW of electricity and four windmills that together produce 5 MW. In 2025, its share price target would be ₹168 as per our analysis.
By our prediction, its share price would be between ₹62 to ₹168 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 62 | 168 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 102 | 145 |
| February | 82 | 134 |
| March | 71 | 96 |
| April | 62 | 78 |
| May | 73 | 86 |
| June | 79 | 90 |
| July | 87 | 97 |
| August | 92 | 121 |
| September | 109 | 129 |
| October | 120 | 143 |
| November | 139 | 162 |
| December | 160 | 168 |
Recently, Its revenue growth has been slower than the average growth in the industry. The company’s market share has also decreased, but its net income has grown faster than most other companies. The promoters’ ownership in the company has been increased over the past few quarters. Their ownership was high compared to the previous year, and there are no loans or debts against their shares. So, In 2026, its share price target would be ₹223 as per our prediction.
Its share price would be between ₹110 to ₹223 in 2026, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 110 | 223 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 160 | 173 |
| February | 150 | 154 |
| March | 142 | 149 |
| April | 132 | 140 |
| May | 110 | 156 |
| June | 143 | 168 |
| July | 158 | 179 |
| August | 165 | 187 |
| September | 176 | 190 |
| October | 183 | 197 |
| November | 191 | 212 |
| December | 209 | 223 |
It is a small-cap company that gives mixed signals about its future. On the positive side, it has had a strong 5-year return and a good performance so far this year. Also, there are concerns because its profit is higher than its revenue, which means its profit margin is unusually large. The company has very little debt and a good cash balance, which are positive signs. It is important to keep an eye on how consistently the company can grow its profit and revenue over time. Overall, it looks like a moderate buy if you’re thinking long-term. In 2027, its share price target would be ₹270 as per our analysis.
By our prediction, its share price would be between ₹140 to ₹270 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 140 | 270 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 209 | 228 |
| February | 178 | 190 |
| March | 163 | 170 |
| April | 140 | 158 |
| May | 152 | 168 |
| June | 163 | 179 |
| July | 173 | 196 |
| August | 190 | 210 |
| September | 205 | 221 |
| October | 217 | 243 |
| November | 237 | 263 |
| December | 254 | 270 |
It works in different fields like Pharmaceuticals, Real Estate, and Power. In Pharmaceuticals, the company makes and sells ingredients used in medicines, which are produced using fermentation and chemical processes. It also does research and development in Vadodara to improve its products. In Real Estate, Alembic builds houses and commercial buildings, offers project management and marketing services, and rents out commercial properties to different businesses.
In Power, the company produces electricity using co-generation plants that generate 11 MW of power and four windmills that produce 5 MW of wind power. In 2028, its share price target would be ₹320 as per our prediction.
Its share price would be between ₹192 to ₹320 in 2028, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 192 | 320 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 254 | 275 |
| February | 221 | 250 |
| March | 200 | 209 |
| April | 192 | 204 |
| May | 200 | 218 |
| June | 209 | 231 |
| July | 220 | 248 |
| August | 233 | 259 |
| September | 254 | 278 |
| October | 263 | 293 |
| November | 287 | 312 |
| December | 308 | 320 |
It has factories in Vadodara, Gujarat, and Solan, Himachal Pradesh. The company was first established in Vadodara to produce tinctures and alcohol. As time passed, it expanded to produce items like cough syrup, vitamins, tonics, and sulfur-based drugs. The company also began making penicillin, streptomycin, and erythromycin with support from Eli Lilly USA.
It launched the brand Althrocin, which became one of the top-selling medicines in India. Later, the company started producing Cephalosporin C and created a fully owned subsidiary to help grow its business and after passing years, it became a strong and reputed company. In 2029, its share price target would be ₹370 as per our analysis.
By our prediction, its share price would be between ₹251 to ₹370 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 251 | 370 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 308 | 328 |
| February | 286 | 297 |
| March | 263 | 274 |
| April | 251 | 262 |
| May | 259 | 275 |
| June | 263 | 287 |
| July | 272 | 300 |
| August | 292 | 313 |
| September | 304 | 321 |
| October | 316 | 346 |
| November | 341 | 362 |
| December | 359 | 370 |
The company introduced a new product called ZERO, which is a sugar substitute with no calories. This helped the company enter the growing market for lifestyle products that people can buy over the counter. The company combined its generic alliances and API division to create a new, separate unit. It also built a new factory in Baddi, Himachal Pradesh, with a very large production capacity.
The company increased the amount of tablets and capsules. It also bought an API plant in Karakhadi, Vadodara. The company took over the Non-Oncology Business of Dabur Pharma Ltd. and made a deal to use its new drug delivery platform for Keppra XR with UCB Belgium. In 2030, its share price target would be ₹434 as per our prediction.
Its share price would be between ₹310 to ₹434 in 2030, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 310 | 434 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 359 | 374 |
| February | 367 | 383 |
| March | 376 | 390 |
| April | 387 | 399 |
| May | 393 | 409 |
| June | 405 | 410 |
| July | 407 | 414 |
| August | 409 | 416 |
| September | 412 | 419 |
| October | 415 | 420 |
| November | 418 | 427 |
| December | 420 | 434 |
The company bought the API manufacturing facility of Nirayu Pvt Ltd, located in Panelav near Vadodara. The company also created a fully owned branch called Alembic Global Holding in Neuchatel, Switzerland. The company’s pharmaceutical business was split and moved to Alembic Pharmaceuticals Limited.
The first real estate project, called Samsara, was completed. The company then started its second real estate project called VEDA. The company also introduced two new APIs. Alembic City Limited, which was once known as Alembic Exports Limited, became a fully owned branch of the company. In 2040, its share price target would be ₹812 as per our analysis.
By our prediction, its share price would be between ₹640 to ₹812 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 640 | 812 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 640 | 656 |
| February | 645 | 673 |
| March | 661 | 688 |
| April | 673 | 693 |
| May | 689 | 710 |
| June | 700 | 726 |
| July | 717 | 736 |
| August | 725 | 745 |
| September | 732 | 768 |
| October | 756 | 779 |
| November | 768 | 790 |
| December | 786 | 812 |
It works in three main areas: making medicines, real estate, and producing power using windmills. It makes important ingredients for medicines and antibiotics like penicillin at plants in Gujarat and Himachal Pradesh. Over time, the company has added new products and bought other businesses, including medicine factories. It is also involved in real estate and has launched several projects in recent years. In 2050, its share price target would be ₹1301 as per our prediction.
Its share price would be between ₹1108 to ₹1301 in 2050, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 1108 | 1301 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1108 | 1132 |
| February | 1121 | 1153 |
| March | 1142 | 1178 |
| April | 1154 | 1186 |
| May | 1173 | 1193 |
| June | 1189 | 1230 |
| July | 1218 | 1239 |
| August | 1228 | 1243 |
| September | 1234 | 1265 |
| October | 1253 | 1278 |
| November | 1262 | 1290 |
| December | 1283 | 1301 |
Should I buy Alembic stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 62 | 168 |
| 2026 | 110 | 223 |
| 2027 | 140 | 270 |
| 2028 | 192 | 320 |
| 2029 | 251 | 370 |
| 2030 | 310 | 434 |
| 2040 | 640 | 812 |
| 2050 | 1108 | 1301 |
It is well-known for its work in medicine, real estate, and power. The company doesn’t have much debt and has good cash flow, which makes it a decent choice for long-term investment. But also, its growth has slowed down, and it’s losing market share, which could be a concern. The stock has been falling recently, so it might not be the best pick for short-term investors. Overall, it could be a good option for long-term investors, but there are some risks to consider in the short term.
Alembic Earning Results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 74 | 74 | 78 | 127 | 157 |
| Expenses + | 71 | 62 | 64 | 87 | 101 |
| Operating Profit | 3 | 11 | 14 | 40 | 57 |
| OPM % | 4% | 15% | 18% | 32% | 36% |
| Other Income + | 93 | 10 | 89 | 54 | 55 |
| Interest | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 3 | 4 | 5 | 7 | 8 |
| Profit before tax | 93 | 17 | 98 | 87 | 103 |
| Tax % | 0% | 19% | 12% | 7% | 10% |
| Net Profit + | 329 | 343 | 222 | 191 | 269 |
| EPS in Rs | 12.82 | 13.35 | 8.65 | 7.42 | 10.46 |
| Dividend Payout % | 5% | 2% | 21% | 30% | 23% |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 8.22 | 1.18 | 2.39% | 47.73 | 6.08 | 0.56% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| Alembic Ltd | 9.62 | 1.18 | 2.39% |
| Sun Pharmaceutical Industries Ltd | 42.01 | 5.99 | 0.81% |
| Cipla Ltd | 28.69 | 4.41 | 0.89% |
| Torrent Pharmaceuticals Ltd | 63.76 | 15.40 | 0.90% |
Is Alembic stock good to buy? (Bull case & bear case)
Bull Case:
- It has been making more money, with both revenue and profit increasing recently, showing they are doing well financially.
- The company has been getting approvals from the U.S. Food and Drug Administration (FDA) for some of its medicines, which helps it expand in the U.S. market.
- It generates revenue from various areas, international sales, domestic sales, and producing ingredients for other companies, which reduces its risks.
- Many analysts believe that Alembic’s stock price could go up, with a target price higher than where it is now.
- The company is almost debt-free, which means it has fewer financial obligations and is less risky.
- It has been paying out a healthy dividend of 24.5%, which is attractive to investors looking for income from their investments.
- The company has improved its debtor days (how long it takes to collect payments from customers) from 61.4 days to 45.8 days, showing better cash flow management. Also, its working capital requirements have reduced from 141 days to 81.2 days, indicating better efficiency.
- The stock is trading at 1.17 times its book value, which may suggest it is priced reasonably relative to its assets.
- It is expected to report strong results in the next quarter, which could boost its stock price.
Bear Case:
- The company’s recent earnings didn’t meet what experts predicted, which could make investors worry about future performance.
- The pharmaceutical industry can be unpredictable, with changes in regulations, prices, and competition that might hurt the company’s profits.
- Its stock has dropped by about 19% over the last year, which might make investors cautious.
- Some experts think the stock might be overvalued, meaning it could fall in price in the short term.
- The company’s tax rate seems low, which could raise questions about its financial practices or future tax liabilities.
- Over the last three years, Alembic has had a low return on equity (ROE) of just 10%, which may concern investors about the company’s ability to generate profits efficiently.
- A portion of Alembic’s earnings includes other income of ₹74.0 crores, which might not be sustainable or related to its core business.
Conclusion
It looks like a good option for long-term investment because it earns money from different areas, has little debt, pays a solid dividend, and is growing in the U.S. market. The company is doing well with its profits and is getting better at managing its cash. But also, there are some short-term risks, like not meeting earnings expectations and market changes, which could make the stock go up and down. Overall, it could be a good pick for long-term growth if you’re okay with some short-term ups and downs.
